Neurogenesis Inc
Neurogenesis, Inc. manufactures and sells nutritional supplements primarily in the United States. The company offers NeuBecalm'd, a nutritional supplement to reduce the effects of acute and chronic stress factors; NeuBecalm'd Chewables that reduces the effects of stress and enhance focus; and NeuRecover, a nutritional support for the natural replenishment of neurotransmitters depleted by the long… Read more
Neurogenesis Inc (NEUN) - Total Liabilities
Latest total liabilities as of September 2011: $139.71K USD
Based on the latest financial reports, Neurogenesis Inc (NEUN) has total liabilities worth $139.71K USD as of September 2011.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Neurogenesis Inc - Total Liabilities Trend (2002–2013)
This chart illustrates how Neurogenesis Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Neurogenesis Inc Competitors by Total Liabilities
The table below lists competitors of Neurogenesis Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Cygnus Oil & Gas Corp
PINK:CYNS
|
USA | $28.63 Million |
|
InRob Tech Ltd
PINK:IRBL
|
USA | $5.07 Million |
|
Caliber Imaging & Diagnostics Inc
PINK:LCDX
|
USA | $16.40 Million |
|
MotorVac Technologies Inc
PINK:MVAC
|
USA | $1.17 Million |
|
Exobox Tech Corp
PINK:EXBX
|
USA | $3.51 Million |
|
Next.e.GO N.V.
NASDAQ:EGOXF
|
USA | $190.03 Million |
|
Gritstone bio, Inc.
NASDAQ:GRTSQ
|
USA | $120.35 Million |
|
Transtech Industries Inc
PINK:TRTI
|
USA | $8.98 Million |
Liability Composition Analysis (2002–2013)
This chart breaks down Neurogenesis Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.10 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.76 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 2.31 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Neurogenesis Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Neurogenesis Inc (2002–2013)
The table below shows the annual total liabilities of Neurogenesis Inc from 2002 to 2013.
| Year | Total Liabilities | Change |
|---|---|---|
| 2013-12-31 | $193.40K | +5.82% |
| 2012-12-31 | $182.76K | -2.30% |
| 2011-12-31 | $187.05K | -3.59% |
| 2006-12-31 | $194.01K | -49.91% |
| 2004-12-31 | $387.37K | -6.71% |
| 2003-12-31 | $415.24K | +8.59% |
| 2002-12-31 | $382.38K | -- |